Shira N. Dinner, MD discussed several studies focused on the treatment of acute lymphoblastic leukemia (ALL) in older adults, particularly those aged 55 and above. The presentation highlighted the challenges and outcomes associated with different treatment approaches.
Shira N. Dinner, MDfirst emphasized the historical poor outcomes for older adults with ALL, with survival rates being notably lower compared to younger patients. The presentation covered studies involving various treatment strategies, including the use of venetoclax, blinatumomab, inotuzumab, and combination therapies.
One study investigated the combination of mini chemotherapy regimen CBD (cyclophosphamide, vincristine, dexamethasone) with inotuzumab and blinatumomab. While showing promising results, the presentation raised concerns about secondary myeloid neoplasms and questioned whether chemotherapy could be further reduced in this population.